A Phase 2 interventional study of Fp MDPI and Placebo MDPI in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 300 sites in 19 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-05-08.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 10th largest by enrollment of the 146 interventional ones that give a count, is one of 13 that started in 2012, is one of 25 in phase 2, and was the 94th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 13 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 889 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
54 studies in Asthma by Teva Pharmaceutical Industries, Ltd.: none open now, 1 under way, 1 of them phase 3. Of 52 finished, 36 (69%) have results posted.
Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., this one is the 7th largest by enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2012, is one of 11 in phase 2, and was the 18th registered.
Teva Pharmaceutical Industries, Ltd.’s Asthma studies by the year they started, since 2003.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among Teva Pharmaceutical Industries, Ltd.’s 54 in Asthma:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the dose response, efficacy and safety of 4 different doses of fluticasone propionate (50, 100, 200, and 400mcg) delivered as Fluticasone Spiromax® Inhalation Powder (Fp Spiromax) when administered twice daily in subjects 12 years of age and older with severe persistent asthma who are uncontrolled on high dose ICS therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Severity of Disease:
Current Asthma Therapy: Subjects will be required to be on a short acting β2 agonist and inhaled for a minimum of 8 weeks before the Screening Visit and have been maintained on a stable dose of inhaled corticosteroids for four weeks prior to the Screening Visit at one of the following doses:
Exception 1: Based upon the investigator's judgment that there is no inherent harm in changing the subject's current ICS/LABA therapy and the subject provides consent, subjects on inhaled Fluticasone propionate/salmeterol DPI ≥ 1000 mcg/day, or Fluticasone propionate/salmeterol HFA ≥ 880 mcg/day, or Fluticasone propionate/Formoterol ≥ 1000 mcg/day,or Beclomethasone dipropionate/Formoterol ≥ 400 mcg/day, or Budesonide/formoterol HFA ≥ 640 mcg/day, or Budesonide/formoterol DPI ≥ 800 mcg/day, or Mometasone furoate/formoterol MDI ≥ 800 mcg/day or subjects on a qualifying ICS dose plus a long-acting β2-agonists (LABA) administered via separate inhalers, may be switched to a qualifying dose of fluticasone propionate provided the subjects will not participate in the PK portion of the study.
Exception 2: Subjects on a qualifying dose of fluticasone propionate who wish to participate in the PK portion of the study and who provide consent may have their fluticasone propionate switched to a different qualifying ICS (non-fluticasone propionate) at a pre-screening visit. The subject will be required to return to the clinic to complete the Screening Visit following a 1-week .
If female, is currently not pregnant, breast feeding, or attempting to become pregnant, has a negative serum pregnancy test, and is of
Non-, defined as:
Child-bearing potential, willing to commit to using a consistent and acceptable method of as defined below for the duration of the study:
Exclusion Criteria:
Any asthma exacerbation requiring oral within 1 month of the Screening Visit. A subject must not have had any hospitalization for asthma within 2 month prior to the Screening Visit.
Note: An exacerbation of asthma is defined as any worsening of asthma requiring any treatment other than rescue albuterol/salbutamol HFA MDI and/or the subject's regular inhaled corticosteroid maintenance treatment. This includes requiring the use of systemic corticosteroids and/or emergency room visit or hospitalization, a change in the subject's regular inhaled corticosteroid maintenance treatment, or the addition of other asthma medications.
Have any of the following conditions that, in the judgment of the investigator, might cause participation in this study to be detrimental to the subject, including, but not limited to:
Use of systemic, oral or depot corticosteroids within 4 weeks prior to the Screening Visit
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.
Drug: Fp MDPI · Drug: albuterol/salbutamol
Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.
Drug: Fp MDPI · Drug: albuterol/salbutamol
Fluticasone propionate (Fp) 200 mcg per dose twice a day (for a total daily dose of 400 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.
Drug: Fp MDPI · Drug: albuterol/salbutamol
Fluticasone propionate (Fp) 400 mcg per dose twice a day (for a total daily dose of 800 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.
Drug: Fp MDPI · Drug: albuterol/salbutamol
Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.
Other: Placebo MDPI · Drug: albuterol/salbutamol
Fluticasone propionate (Fp) 250 mcg per dose twice a day (for a total daily dose of 500 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.
Drug: Flovent Diskus · Drug: albuterol/salbutamol
Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. During the treatment period, participants were randomized to 50, 100, 200 or 400 mcg of Fp one inhalation twice a day for a total daily dose of 100, 200, 400 or 800 mcg. Study drug was administered in the morning and in the evening.
Also known as: fluticasone propionate, Fp SPIROMAX® Inhalation Powder
Placebo multidose dry powder inhaler (MDPI) in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 250 mcg was used twice a day, once in the morning and evening, for a total daily dose of 500 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
Also known as: Fluticasone propionate
Drug page: Albuterol
A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Also known as: short-acting β2-adrenergic agonists
Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period
Trough FEV1 was measured electronically by spirometry at morning (AM) investigational site visits, before administration of the AM dose of study drug, and before albuterol/salbutamol administration. The highest FEV1 value from 3 acceptable and 2 reproducible maneuvers was used. All FEV1 data were submitted to a central reading center for evaluation. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline FEV1 + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.
Time frame: Baseline (Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period
Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (non-missing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.
Time frame: Baseline (Days -6 to Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period
Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. PM PEF baseline was defined as the average of recorded (nonmissing) PM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.
Time frame: Baseline (Days -6 to Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12
The Kaplan-Meier Estimate Of The Probability Of Remaining In The Study At Week 12
The analysis of probability of remaining in the study at Week 12 used the time to patient withdrawal for worsening asthma. Worsening asthma was defined as: 1. clinic visit FEV1 below the FEV1 stability limit value calculated on Day 1. 2. any 7-day run-in or treatment window (using information from the patient diary) during which the subject experienced: * 3 or more days in which the highest PEF has fallen below the PEF stability limit calculated on Day 1 * 3 or more days in which ≥12 inhalations/day of albuterol/salbutamol was used * 2 or more days in which the subject experienced a nighttime asthma symptom score of \>2 3. clinical asthma exacerbation, defined as worsening asthma requiring any treatment other than study drug or rescue albuterol/salbutamol including the use of systemic corticosteroids and/or ER visit or hospitalization. Patients who had withdrawn due to reasons other than worsening asthma were right-censored at the date of last assessment.
Time frame: Day 1 to Week 12
Change From Baseline In The Percentage Of Rescue-Free 24-Hour Periods
The change from baseline in the percentage of rescue-free 24-hour periods was analyzed with a marginal (also called population averaged) logistic model, with the response being the proportion of rescue-free 24-hour periods. The model included 2 time points of measurement for each subject: the baseline (the last 7 days before the treatment period) and the treatment period. The model contained covariates for sex, age, and treatment. Rescue-free days were as indicated in patient diaries. Data values are estimated means.
Time frame: Baseline (Day -6 to Day 1 predose), Treatment (Day 1 to Week 12)
Area Under The Plasma Concentration-Time Curve From Time Zero To The Time Of The Last Measurable Concentration (AUC0-t)
Time frame: Day 1 predose (within 10 minutes of treatment administration), and 5, 10, 15, 30, and 45 minutes, 1 hour, 1 hour 15 minutes, 1 hour 30 minutes, and 2, 4, 8, and 12 hours postdose
Maximum Observed Plasma Concentration (Cmax)
Time frame: Day 1 predose (within 10 minutes of treatment administration), and 5, 10, 15, 30, and 45 minutes, 1 hour, 1 hour 15 minutes, 1 hour 30 minutes, and 2, 4, 8, and 12 hours postdose
Time Of Maximum Observed Plasma Concentration (Tmax)
Time frame: Day 1 predose (within 10 minutes of treatment administration), and 5, 10, 15, 30, and 45 minutes, 1 hour, 1 hour 15 minutes, 1 hour 30 minutes, and 2, 4, 8, and 12 hours postdose
Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
Time frame: Day 1 to Week 12
Patients With Positive Swab Test Results for Oral Candidiasis
Oropharyngeal examinations for visual evidence of oral candidiasis were conducted at each visit. Any visual evidence of oral candidiasis during the oropharyngeal exam was evaluated by obtaining and analyzing a swab of the suspect area. This outcomes indicates how many patients had positive swab test results. The total number of patients who had oropharyngeal exams at each timepoint are specified in the timepoint field. Appropriate therapy was to be initiated immediately at the discretion of the investigator and was not to be delayed for culture confirmation. Subjects with a culture-positive infection could continue participation in the study on appropriate anti-infective therapy, provided this therapy was not prohibited by the protocol.
Time frame: Screening (Days -21 to -14), Randomization (Day 1), Weeks 1, 2, 3, 4, 6, 8, 10, 12
24-Hour Urinary Cortisol Excretion at Baseline, Week 12 and Endpoint
24-hour urinary cortisol excretion was determined from 24-hour pooled-urine samples; urine was refrigerated until return to the investigational site after each 24-hour collection period. Urine was collected within 7 days of Day 1 and within 7 days of Week 12. Urine cortisol sample collection was not required at endpoint visit for subjects who terminated early from the study.
Time frame: Baseline (Day 1), Week 12, Endpoint
Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)
Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (nonmissing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to Flovent Diskus are from an MMRM model which includes data from all treatments: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.
Time frame: Baseline (Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)
Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (nonmissing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to Flovent Diskus are from an MMRM model that included data for all treatments: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.
Time frame: Baseline (Days -6 to Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)
Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. PM PEF baseline was defined as the average of recorded (nonmissing) PM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to Flovent Diskus are from an MMRM model that included data for all treatments: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.
Time frame: Baseline (Days -6 to Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12
| Milestone | Placebo MDPI (Run-In) | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|---|
| Started | 889 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 640 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 249 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Inclusion/exclusion criteria | 49 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 17 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomization criteria not met | 166 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 15 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo MDPI (Run-In) | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|---|
| Started | 0 | 107 | 107 | 106 | 107 | 106 | 107 |
| Safety population | 0 | 107 | 107 | 106 | 107 | 106 | 106 |
| Efficacy population (full analysis set) | 0 | 107 | 106 | 102 | 107 | 105 | 103 |
| Completed | 0 | 82 | 87 | 75 | 80 | 58 | 77 |
| Not completed | 0 | 25 | 20 | 31 | 27 | 48 | 30 |
| Withdrew: Adverse event | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 | 2 | 4 | 2 |
| Withdrew: Physician decision | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 5 | 4 | 10 | 6 | 8 | 12 |
| Withdrew: Sponsor request | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Met stopping criteria | 0 | 16 | 13 | 19 | 16 | 33 | 15 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Noncompliance to study medication | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Trough FEV1 was measured electronically by spirometry at morning (AM) investigational site visits, before administration of the AM dose of study drug, and before albuterol/salbutamol administration. The highest FEV1 value from 3 acceptable and 2 reproducible maneuvers was used. All FEV1 data were submitted to a central reading center for evaluation. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline FEV1 + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.
| liters | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|
| Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period | 0.059 ± 0.0269 | 0.101 ± 0.0268 | 0.109 ± 0.0278 | 0.125 ± 0.0274 | 0.053 ± 0.0283 | — |
Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (non-missing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.
| liters/minute | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|
| Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period | 10.48 ± 4.299 | 9.34 ± 4.245 | 10.03 ± 4.420 | 9.61 ± 4.307 | 2.24 ± 4.507 | — |
Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. PM PEF baseline was defined as the average of recorded (nonmissing) PM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.
| liters/minute | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|
| Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period | 3.81 ± 4.183 | 6.41 ± 4.209 | 7.45 ± 4.335 | 10.97 ± 4.208 | 3.42 ± 4.462 | — |
The analysis of probability of remaining in the study at Week 12 used the time to patient withdrawal for worsening asthma. Worsening asthma was defined as: 1. clinic visit FEV1 below the FEV1 stability limit value calculated on Day 1. 2. any 7-day run-in or treatment window (using information from the patient diary) during which the subject experienced: * 3 or more days in which the highest PEF has fallen below the PEF stability limit calculated on Day 1 * 3 or more days in which ≥12 inhalations/day of albuterol/salbutamol was used * 2 or more days in which the subject experienced a nighttime asthma symptom score of \>2 3. clinical asthma exacerbation, defined as worsening asthma requiring any treatment other than study drug or rescue albuterol/salbutamol including the use of systemic corticosteroids and/or ER visit or hospitalization. Patients who had withdrawn due to reasons other than worsening asthma were right-censored at the date of last assessment.
| probability | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|
| The Kaplan-Meier Estimate Of The Probability Of Remaining In The Study At Week 12 | 0.6872 (0.5891 to 0.7665) | 0.6330 (0.5307 to 0.7188) | 0.5852 (0.4796 to 0.6766) | 0.6109 (0.5093 to 0.6977) | 0.4722 (0.3712 to 0.5665) | 0.5657 (0.4617 to 0.6571) |
The change from baseline in the percentage of rescue-free 24-hour periods was analyzed with a marginal (also called population averaged) logistic model, with the response being the proportion of rescue-free 24-hour periods. The model included 2 time points of measurement for each subject: the baseline (the last 7 days before the treatment period) and the treatment period. The model contained covariates for sex, age, and treatment. Rescue-free days were as indicated in patient diaries. Data values are estimated means.
| percentage of total 24 hour periods | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|
| Change From Baseline In The Percentage Of Rescue-Free 24-Hour Periods | 22.78 ± 4.016 | 26.41 ± 4.013 | 16.18 ± 3.662 | 28.05 ± 3.951 | 27.15 ± 4.475 | 15.87 ± 3.750 |
| pg*hr/mL | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|
| Area Under The Plasma Concentration-Time Curve From Time Zero To The Time Of The Last Measurable Concentration (AUC0-t) | 117.6 ± 145.79 | 126.8 ± 33.73 | 292.0 ± 162.28 | 462.8 ± 262.45 | — | 162.3 ± 74.79 |
| pg/mL | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 19.1 ± 15.53 | 26.5 ± 6.16 | 55.2 ± 29.12 | 83.0 ± 44.32 | — | 32.5 ± 13.92 |
| hours | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|
| Time Of Maximum Observed Plasma Concentration (Tmax) | 1.0 ± 0.54 | 1.2 ± 1.85 | 2.2 ± 3.58 | 1.4 ± 2.60 | — | 1.8 ± 2.75 |
An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
| participants | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|
| Any adverse event (AE) | 31 | 27 | 34 | 41 | 33 | 27 |
| Severe AE | 3 | 1 | 1 | 1 | 1 | 0 |
| Treatment-related AE | 4 | 1 | 6 | 9 | 5 | 2 |
| Deaths | 0 | 0 | 0 | 0 | 0 | 0 |
| Other serious AEs | 1 | 1 | 1 | 0 | 1 | 0 |
| Withdrawn from treatment due to AEs | 1 | 1 | 1 | 1 | 1 | 0 |
Oropharyngeal examinations for visual evidence of oral candidiasis were conducted at each visit. Any visual evidence of oral candidiasis during the oropharyngeal exam was evaluated by obtaining and analyzing a swab of the suspect area. This outcomes indicates how many patients had positive swab test results. The total number of patients who had oropharyngeal exams at each timepoint are specified in the timepoint field. Appropriate therapy was to be initiated immediately at the discretion of the investigator and was not to be delayed for culture confirmation. Subjects with a culture-positive infection could continue participation in the study on appropriate anti-infective therapy, provided this therapy was not prohibited by the protocol.
| participants | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|
| Screening | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 1 | 0 | 0 | 1 | 0 | 1 | 1 |
| Week 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Week 2 | 0 | 0 | 1 | 2 | 0 | 0 |
| Week 3 | 0 | 0 | 0 | 4 | 0 | 0 |
| Week 4 | 1 | 0 | 1 | 1 | 0 | 0 |
| Week 6 | 0 | 0 | 0 | 1 | 0 | 0 |
| Week 8 | 0 | 0 | 1 | 0 | 0 | 1 |
| Week 10 | 0 | 0 | 0 | 1 | 0 | 0 |
| Week 12 | 0 | 0 | 0 | 1 | 0 | 1 |
24-hour urinary cortisol excretion was determined from 24-hour pooled-urine samples; urine was refrigerated until return to the investigational site after each 24-hour collection period. Urine was collected within 7 days of Day 1 and within 7 days of Week 12. Urine cortisol sample collection was not required at endpoint visit for subjects who terminated early from the study.
| nmol/day | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|
| Baseline | 65.3 ± 42.69 | 63.8 ± 44.70 | 66.6 ± 45.53 | 57.4 ± 34.68 | 74.3 ± 43.54 | 66.2 ± 42.68 |
| Week 12 | 71.8 ± 48.37 | 61.5 ± 45.73 | 66.8 ± 53.96 | 46.2 ± 38.67 | 69.2 ± 49.56 | 58.5 ± 43.75 |
| Endpoint | 71.0 ± 48.31 | 61.5 ± 45.73 | 65.8 ± 53.33 | 45.0 ± 38.33 | 74.4 ± 54.97 | 58.4 ± 43.49 |
Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (nonmissing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to Flovent Diskus are from an MMRM model which includes data from all treatments: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.
| liters | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|
| Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm) | 0.063 ± 0.027 | 0.102 ± 0.0269 | 0.113 ± 0.0279 | 0.129 ± 0.0274 | 0.057 ± 0.0284 | 0.110 ± 0.0274 |
Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (nonmissing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to Flovent Diskus are from an MMRM model that included data for all treatments: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.
| liters/minute | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|
| Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm) | 10.85 ± 4.245 | 9.39 ± 4.193 | 10.29 ± 4.362 | 10.40 ± 4.254 | 2.52 ± 4.453 | 15.97 ± 4.283 |
Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. PM PEF baseline was defined as the average of recorded (nonmissing) PM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to Flovent Diskus are from an MMRM model that included data for all treatments: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.
| liters/minute | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg |
|---|---|---|---|---|---|---|
| Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm) | 4.22 ± 4.245 | 6.52 ± 4.275 | 7.89 ± 4.397 | 11.72 ± 4.271 | 3.35 ± 4.518 | 12.4 ± 4.309 |
Collected over Day 1 to Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Flovent Diskus 250 mcg | — | 0/106 (0%) | 4/106 (3.8%) |
| Fp MDPI 100 mcg | — | 1/107 (0.9%) | 4/107 (3.7%) |
| Fp MDPI 200 mcg | — | 1/106 (0.9%) | 5/106 (4.7%) |
| Fp MDPI 400 mcg | — | 0/107 (0%) | 7/107 (6.5%) |
| Fp MDPI 50 mcg | — | 1/107 (0.9%) | 5/107 (4.7%) |
| Placebo MDPI | — | 1/106 (0.9%) | 6/106 (5.7%) |
| Event | Flovent Diskus 250 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Fp MDPI 50 mcg | Placebo MDPI |
|---|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/106 | 0/107 | 1/106 | 0/107 | 0/107 | 0/106 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/106 | 0/107 | 0/106 | 0/107 | 0/107 | 1/106 |
| Kidney infectionInfections and infestations | 0/106 | 1/107 | 0/106 | 0/107 | 0/107 | 0/106 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/106 | 0/107 | 0/106 | 0/107 | 1/107 | 0/106 |
| Event | Flovent Diskus 250 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Fp MDPI 50 mcg | Placebo MDPI |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 4/106 | 4/107 | 5/106 | 7/107 | 5/107 | 6/106 |
Intent to treat analysis set
| Age, Continuous(years) | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 47.9 ± 14.59 | 48.7 ± 12.48 | 47.7 ± 14.18 | 50.9 ± 13.32 | 49.8 ± 12.87 | 49.2 ± 13.26 | 49.0 ± 13.46 |
| Age, Customized(participants) | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg | Total |
|---|---|---|---|---|---|---|---|
| Adolescents (12-17 years) | 2 | 3 | 1 | 1 | 1 | 1 | 9 |
| Adults (18-64 years) | 94 | 99 | 90 | 90 | 94 | 96 | 563 |
| Adults (65-84 years) | 11 | 5 | 15 | 16 | 11 | 10 | 68 |
| Sex: Female, Male(Participants) | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg | Total |
|---|---|---|---|---|---|---|---|
| Female | 63 | 55 | 66 | 72 | 65 | 58 | 379 |
| Male | 44 | 52 | 40 | 35 | 41 | 49 | 261 |
| Race/Ethnicity, Customized(participants) | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg | Total |
|---|---|---|---|---|---|---|---|
| White | 96 | 94 | 93 | 91 | 96 | 95 | 565 |
| Black | 9 | 12 | 12 | 13 | 8 | 11 | 65 |
| Asian | 1 | 1 | 1 | 2 | 2 | 0 | 7 |
| American Indian or Alaskan Native | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(participants) | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 7 | 8 | 12 | 6 | 9 | 47 |
| Not Hispanic or Latino | 102 | 100 | 98 | 95 | 100 | 98 | 593 |
| Weight(kg) | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 86.7 ± 23.73 | 86.6 ± 22.90 | 84.4 ± 21.89 | 84.4 ± 20.56 | 86.2 ± 25.19 | 83.3 ± 16.76 | 85.3 ± 21.95 |
| Height(cm) | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 169.4 ± 13.04 | 168.7 ± 9.14 | 168.4 ± 7.86 | 167.4 ± 9.67 | 168.1 ± 8.57 | 168.0 ± 8.33 | 168.3 ± 9.58 |
| Body Mass Index(kg/m^2) | Fp MDPI 50 mcg | Fp MDPI 100 mcg | Fp MDPI 200 mcg | Fp MDPI 400 mcg | Placebo MDPI | Flovent Diskus 250mcg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 31.3 ± 17.88 | 30.4 ± 7.60 | 29.8 ± 8.12 | 30.1 ± 6.81 | 30.5 ± 8.83 | 29.6 ± 6.03 | 30.3 ± 10.02 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 300 sites across 19 countries. Choose a country and city above to see the rest.
The record gives a start of Apr 2012, a primary completion of Jul 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 3 years 9 months after primary completion. A results delay was requested in Mar 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone
Teva Branded Pharmaceutical Products R&D, Inc. →